Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery.

Journal Article (Journal Article;Multicenter Study)

OBJECTIVES: The CoreValve Extreme Risk US Pivotal Trial enrolled patients with symptomatic severe aortic stenosis deemed unsuitable for surgical aortic valve replacement. Implants were attempted using transfemoral access (n = 489) or an alternative access (n = 150). In present analysis, we sought to examine the safety and efficacy of CoreValve transcatheter aortic valve replacement using alternative access. METHODS: The present study included 150 patients with prohibitive iliofemoral anatomy who were treated with the CoreValve transcatheter heart valve delivered by way of the subclavian artery (n = 70) or a direct aortic approach (n = 80). The echocardiograms were read by an independent core laboratory. The primary endpoint was all-cause mortality or major stroke at 12 months. RESULTS: The preoperative aortic valve area was 0.72 ± 0.27 cm(2) and mean aortic valve gradient was 49.5 ± 17.0 mm Hg. After the transcatheter aortic valve replacement, the effective aortic valve area was 1.82 ± 0.64 cm(2) at 1 month and 1.85 ± 0.51 cm(2) at 12 months. The mean aortic valve gradient was 9.7 ± 5.8 mm Hg at 30 days and 9.5 ± 5.7 mm Hg at 12 months. The death or major stroke rate was 15.3% at 30 days and 39.4% at 12 months. The individual rate of all-cause mortality and major stroke was 11.3% and 7.5% at 30 days and 36.0% and 9.1% at 12 months. CONCLUSIONS: These data demonstrate that the CoreValve transcatheter heart valve delivered by an alternative access provides a suitable alternative for treatment of extreme risk patients with symptomatic severe aortic stenosis, who have prohibitive iliofemoral anatomy and no surgical options.

Full Text

Duke Authors

Cited Authors

  • Reardon, MJ; Adams, DH; Coselli, JS; Deeb, GM; Kleiman, NS; Chetcuti, S; Yakubov, SJ; Heimansohn, D; Hermiller, J; Hughes, GC; Harrison, JK; Khabbaz, K; Tadros, P; Zorn, GL; Merhi, W; Heiser, J; Petrossian, G; Robinson, N; Maini, B; Mumtaz, M; Lee, JS; Gleason, TG; Resar, J; Conte, J; Watson, D; Chenoweth, S; Popma, JJ; CoreValve US Clinical Investigators,

Published Date

  • December 2014

Published In

Volume / Issue

  • 148 / 6

Start / End Page

  • 2869-76.e1-7 -

PubMed ID

  • 25152474

Pubmed Central ID

  • 25152474

Electronic International Standard Serial Number (EISSN)

  • 1097-685X

Digital Object Identifier (DOI)

  • 10.1016/j.jtcvs.2014.07.020


  • eng

Conference Location

  • United States